Siltuximab downregulates interleukin-8 and pentraxin 3 to improve ventilatory status and survival in severe COVID-19
This article has been Reviewed by the following groups
Listed in
- Evaluated articles (ScreenIT)
Abstract
Article activity feed
-
-
-
SciScore for 10.1101/2020.04.01.20048561: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement IRB: The study protocol was submitted and approved through the Hospital Ethics Board. Patients, or their legal representative, provided either verbal or written consent to participate in the study. Randomization not detected. Blinding not detected. Power Analysis not detected. Sex as a biological variable not detected. Table 2: Resources
Software and Algorithms Sentences Resources All statistical analyses were performed with SAS® software (Version 9.4 or later). SAS®suggested: (SASqPCR, RRID:SCR_003056)Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from …SciScore for 10.1101/2020.04.01.20048561: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement IRB: The study protocol was submitted and approved through the Hospital Ethics Board. Patients, or their legal representative, provided either verbal or written consent to participate in the study. Randomization not detected. Blinding not detected. Power Analysis not detected. Sex as a biological variable not detected. Table 2: Resources
Software and Algorithms Sentences Resources All statistical analyses were performed with SAS® software (Version 9.4 or later). SAS®suggested: (SASqPCR, RRID:SCR_003056)Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:Our study has several limitations. It is an observational study with a small sample size, which limits the interpretation and generalisability of the results. Due to the observational study design, we cannot exclude the possibility of unmeasured confounding factors, although we have reassuringly noted consistency in the propensity score-matched analyses. No data were available for laboratory parameters and adverse events in the control cohort, meaning that comparisons between treated and untreated patients were not possible. Nonetheless, there is a sound rationale for the use of siltuximab in this patient group, and there were improvements in mortality and patient outcomes. In summary, our study indicates that siltuximab administered at the onset of ventilatory support reduces mortality associated with COVID-19 and respiratory failure compared with best supportive care. Further randomised controlled studies are needed to confirm the efficacy and safety of this IL-6 neutralising mAb in the treatment of patients with COVID-19 and respiratory failure.
Results from TrialIdentifier: We found the following clinical trial numbers in your paper:
Identifier Status Title NCT04322188 Completed An Observational Study of the Use of Siltuximab (SYLVANT) in… Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
-
-
-